Variation Biotechnologies to Present Positive Influenza Vaccine Data at the 49th Annual ICAAC Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 11, 2009 - Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today announced that it plans to present positive results from a preclinical study of the company's proprietary influenza vaccine at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), being held at the Moscone Convention Center in San Francisco, California.
Dr. David E. Anderson, Vice President, Immunology and co-founder of Variation, will present the poster, entitled, “Efficacy and Broadly Reactive Immunity Directed Against Seasonal and Pandemic Strains of Influenza Using VariositeTM Technology,” on Sunday, September 13 from 11:15 am – 1:15 pm in Hall B of the Moscone Center. The presentation will be made available on the Variation website, www.variationbiotech.com on Monday, September 14.
“These data demonstrate the potential of our influenza vaccine and establish our VariositeTM technology as a novel means of developing vaccines that induce broadly reactive immunity to protect against infection by variable pathogens,” said Dr. Anderson. “We are extremely proud to have been selected to present these data at the 49th Annual ICAAC meeting, and are thankful to the meeting organizers for this opportunity.”
Variation Biotechnologies, Inc. (VBI) is a leader in the discovery and development of novel vaccines to fight infectious diseases, including seasonal and pandemic influenza, hepatitis and HIV. The company utilizes its proprietary VariositeTM technology to design vaccines with broad immunity and is also developing a proprietary technology to enable convenient oral administration. VBI's lead candidates include a multi-season parenteral vaccine to fight influenza and an orally-delivered vaccine to address hepatitis A. For more information please visit Variation's website, www.variationbiotech.com.
Contact: Variation Biotechnologies, Inc.
Adam Buckley, B.Sc, M.B.A., 613-749-4200 x122
Director of Corporate Development
Red Mountain Communications
Jonathan M. Nugent, 205-566-3026
Posted: September 2009